Education
About Us
Working with TipRanks
Follow Us
Tissue Repair Ltd (AU:TRP)
ASX:TRP
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.16 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$9.98M
Enterprise ValueAU$1.68M
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationA multi-fold revenue increase in 2025 demonstrates tangible commercial or clinical monetisation progress and growing demand for the company’s outputs. Durable revenue momentum supports scaling of operations, improves unit economics potential, and underpins longer-term business viability if sustained.
High Gross MarginsConsistently very high gross margins indicate the underlying technology or products carry strong per-unit economics. That structural margin advantage gives flexibility to fund R&D or absorb SG&A while leaving a clearer path to profitability if revenue growth continues and operating expense growth is controlled.
Debt-free Balance SheetA zero-debt capital structure materially reduces insolvency and interest-rate risk, giving management flexibility to prioritise R&D, partnerships, or equity financing. This conservatism preserves strategic optionality and lowers fixed-cost leverage pressure over the medium term.
Bears Say
Persistent Operating LossesOngoing operating losses are a structural drag that erode equity and limit internal funding of growth. Persistent negative operating results imply continual reliance on external capital or dilution, and they reduce return on equity, constraining long-term shareholder value if unaddressed.
Negative Free Cash FlowMaterial negative operating and free cash flow reflect a sustained cash burn profile that shortens runway and increases financing risk. Durable cash outflows force management to secure external funding or partnerships, raising dilution and execution risk for multi-period product development.
Declining Shareholder EquitySteady erosion of equity over several years signals cumulative losses and weak capital retention. Reduced book equity limits the company’s buffer against adverse outcomes, increases sensitivity to future losses, and heightens the probability of dilutive capital raises to sustain operations.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.15 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$9.98M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 165 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Feb 19, 2026. The company reported -AU$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.036.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRP Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$8.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-26.53%
Trailing 12-Months
Asset Growth
-24.84%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―